Compare ADMA Biologics Inc (ADMA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs ProShares UltraPro S&P500 — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while ProShares UltraPro S&P500 trades at $139.94. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | UPRO | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.38 | $150.93 |
52-Week Low | $7.60 | $89.29 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
UPRO, the ProShares UltraPro S&P 500 ETF, trades at $144.41, up 2.64% with a bullish technical outlook from moving averages. The leveraged ETF faces neutral sentiment from oscillators while tracking S&P 500 performance. Recent news highlights sector rotation from tech stocks and mixed analyst views on S&P 500 targets ranging from 8,000 to 8,800 by year-end 2026.
The leveraged structure amplifies both gains and losses, making UPRO suitable for short-term trading amid expected S&P 500 volatility. Key risks include Fed policy uncertainty and sector rotation pressures, while opportunities exist if the S&P 500 reaches analyst targets. Earnings season performance and AI sector momentum remain critical catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
